Journal
VASCULAR PHARMACOLOGY
Volume 150, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.vph.2023.107172
Keywords
Atherosclerosis; Inflammation; Bruton's tyrosine kinase; Mast cell; B cell
Categories
Ask authors/readers for more resources
Atherosclerosis is characterized by the accumulation of lipids and immune cells in the arterial wall. Mast cells play a role in plaque growth and destabilization. The Fc epsilon RI-IgE pathway and BTK may be potential therapeutic targets in atherosclerosis.
Atherosclerosis is characterized by the accumulation of lipids and immune cells, including mast cells and B cells, in the arterial wall. Mast cells contribute to atherosclerotic plaque growth and destabilization upon active degranulation. The Fc epsilon RI-IgE pathway is the most prominent mast cell activation route. Bruton's Tyrosine Kinase (BTK) is involved in Fc epsilon RI-signaling and may be a potential therapeutic target to limit mast cell activation in atherosclerosis. Additionally, BTK is crucial in B cell development and B-cell receptor signaling. In this project, we aimed to assess the effects of BTK inhibition on mast cell activation and B cell development in atherosclerosis. In human carotid artery plaques, we showed that BTK is primarily expressed on mast cells, B cells and myeloid cells. In vitro, BTK inhibitor Acalabrutinib dose-dependently inhibited IgE mediated activation of mouse bone marrow derived mast cells. In vivo, male Ldlr- /- mice were fed a high-fat diet for eight weeks, during which mice were treated with Acalabrutinib or control solvent. In Acalabrutinib treated mice, B cell maturation was reduced compared to control mice, showing a shift from follicular II towards follicular I B cells. Mast cell numbers and activation status were not affected. Acalabrutinib treatment did not affect atherosclerotic plaque size or morphology. In advanced atherosclerosis, where mice were first fed a high-fat diet for eight weeks before receiving treatment, similar effects were observed. Conclusively, BTK inhibition by Acalabrutinib alone did neither affect either mast cell activation nor earlyand advanced atherosclerosis, despite the effects on follicular B cell maturation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available